Diagnostics World | A pioneering program of Geisinger Health System has returned clinically actionable results from exome sequencing to a record-breaking 3,400 individuals at increased risk for potentially life-threatening conditions such as hereditary breast and colon cancers, familial hypercholesterolemia (FH), and heart disease. The MyCode Community Health Initiative, enabled by a 2014 agreement with Regeneron Pharmaceuticals, draws from participants in a sizable DNA biobank who agree to the sequencing and results reporting.
May 11, 2022